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Abstract 
 
Aim: To learn more about percutaneous absorption of the photoactive compound benzophenone-3 
(BZ-3) and to study the excretion pattern of BZ-3 and its metabolite dihydroxy benzophenone (DHB). 
We also got the opportunity to develop a reverse-phase HPLC method to analyze BZ-3 and DHB. The 
photostability of seven commercial sunscreens was also studied. 
 
Material and methods: Paper I: 11 participants applied a sunscreen, 2 mg/cm2, containing 4% BZ-3. 
They collected urine for 48 hours after the application. Paper II: 26 participants applied a sunscreen,   
2 mg/cm2, containing 4% BZ-3 morning and night for five days. Half of the participants were exposed 
to UV radiation (UVR). They collected urine for the five days the sunscreen was applied and an 
additional five days after the last application. Paper III: The assay uses: solid-phase extraction with C8 
columns; a Genesis C18 column (4.6 mm x 150 mm ); a gradient acetonitrile-water mobile phase; a 
UV-detector set at 287 nm. Paper IV: Seven commercial sunscreens were studied with absorption 
spectrophotometry. Sunscreen product, 0.5 mg/cm2, was placed between plates of silica. The area 
under the curve (AUC) in the spectrum was calculated for the different UV regions. AUC before 
(AUCbefore) and after (AUCafter) artificial UV exposure and before and after natural UV exposure were 
calculated. If the AUC Index (AUCI), defined as AUCI=AUCafter/AUCbefore, was > 0.80, the sunscreen 
was considered photostable. 
 
Results: Paper I: The average total amount excreted was 11 mg, median 9.8 mg, which is 
approximately 0.4% of the applied amount BZ-3. Paper II: The volunteers excreted 1.2-8.7% BZ-3 of 
the total applied amount. The mean value found was 3.7%. There was no significant difference 
between the two groups; p<0.99. Paper III: The assay was linear r2 >0.99, with detection limits for  
BZ-3 and DHB of 0.01 µmol/l and 0.16 µmol/l respectively. Relative standard deviation was less than 
10% for BZ-3 and less than 13% for DHB. The excretion pattern varied among the human volunteers, 
different patterns were discerned among the individuals. Paper IV: Three sunscreens were unstable 
after 90 min of natural UV, in the UVA range the AUCI was between 0.41 and 0.76. In the UVB range, 
one of these sunscreens was unstable with an AUCI of 0.75 after 90 min. Three sunscreens were 
photostable after 120 min of natural UV, in the UVA range the AUCI was between 0.85 and 0.99 and in 
the UVB range between 0.92 and 1.0. 
 
Conclusions: Paper I: BZ-3 is absorbed by the skin and excreted in the urine after one topical 
application of a sunscreen containing 4% BZ-3. There are individual differences in the amount 
excreted and in the excretion pattern. Paper II: Repeated topical applications of a sunscreen 
containing 4% BZ-3 lead to a higher excretion of BZ-3. There was no statistical difference after 
exposure to UVR. Paper III: The developed reverse-phase HPLC-method was reliable and suitable to 
handle a large number of samples. BZ-3 and DHB were excreted in a similar pattern. Paper IV: Three 
of the seven investigated sunscreens were photounstable in the UVA region. The combination 
ethylhexyl methoxycinnamate and butyl methoxydibenzoylmethane was unstable regardless of which 
other photoactive compound that was included in the sunscreen. 
 
Key words: benzophenone-3, dihydroxy benzophenone, sunscreens, UV radiation, reverse-phase 
HPLC, photostability  
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Mad Dogs and Englishmen  
 
 
by Noel Coward (1899-1999) 
 
 
In tropical climes there are certain times of day  
When all the citizens retire to tear their clothes off and perspire.  
It's one of the rules that the greatest fools obey,  
Because the sun is much too sultry  
And one must avoid its ultry-violet ray.  
The natives grieve when the white men leave their huts,  
Because they're obviously, definitely nuts!  
Mad dogs and Englishmen go out in the midday sun,  
The Japanese don´t care to, the Chinese wouldn´t dare to,  
Hindus and Argentines sleep firmly from twelve to one  
But Englishmen detest-a siesta.  
In the Philippines they have lovely screens to protect you from the glare.  
In the Malay States, there are hats like plates which the Britishers won't wear.  
At twelve noon the natives swoon and no further work is done,  
But mad dogs and Englishmen go out in the midday sun.  
… 
With kind permission of NC Aventales AG 
MAD DOGS AND ENGLISHMEN © 1930 NC Aventales AG 
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INTRODUCTION 
And God said, “Let there be light,” and there was light - those are among the first 
words in the Holy Bible. The sun has been worshipped since the early days of 
mankind and plays an important role in many religions. In ancient Egypt (2700-2270 
BC), Ra was the sun god, creator of everything.  
The sun is the reason we can live on Earth; it emits visible light, heat and ultraviolet 
radiation (UVR) which are mandatory for life. UVR is necessary in order to synthesize 
vitamin D. Vitamin D in turn is essential for our bone health, and deficiency of vitamin 
D can be related to autoimmune diseases as well to several sorts of cancer. 
Visible light plays a crucial role in photosynthesis, the process whereby plants, algae 
and some bacteria transform carbon dioxide and water to carbohydrate and oxygen. 
Almost all oxygen in the atmosphere is produced by photosynthesis. 
 
Unfortunately the sun also has negative effects on humans, animals, plants and even 
inanimate materials such as paint and plastic. The UVR can cause erythema, skin 
cancer and cataract. Beneficially for us, part of the produced oxygen is transformed 
to ozone in the stratosphere which protects us from the harmful effects of UVR [1]. 
Other means of protection is the use of e.g. sunscreens. 
 
This thesis deals with questions about sunscreens. We have studied the 
percutaneous absorption of BZ-3 and photostability. In the next sections I have 
presented an overview of some topics which are of relevance when dealing with 
sunscreens.  
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THE SKIN 
The human skin consists of three layers. The outer part is the epidermis, which is 
usually between 75 and 150 μm in thickness. It consists mainly of keratinocytes, but 
also of melanocytes, Langerhans cells and Merkel cells. The Langerhans cells are 
part of the immune system and the Merkel cells are part of the nerve system. The 
melanocytes contain pigment and are the most important factor for the color of the 
skin. The outermost part of the epidermis is called the stratum corneum. The stratum 
corneum consists of corneocytes, which are flat, dead keratinocytes with no nucleus 
The matrix consists of lipids arranged in lamellar sheets.This thin layer provides an 
effective barrier against water loss, trauma and microorganisms. The second layer, 
the dermis, supports the epidermis. It consists of connective tissue. The third layer, 
the subcutis, consists of loose connective tissue and fat cells [2, 3]. Figure 1 shows a 
schematic structure of the skin and Figure 2 shows a histological picture of normal 
skin. 
 
 
 
 
Figure 1 Schematic structure of the skin [4]. 
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Figure 2 Histological picture of normal skin [5]. 
 
 
 
In 1975, TB Fitzpatrick developed a classification system for skin (Table 1) [6]. 
According to its ability to tan, the skin is classified into six different types. This 
classification can be helpful, but it is important to remember that there are fair-
skinned Asians and Indians who may be better classified as skintype II-IV. 
 
 
 
Table 1 Fitzpatrick skin types (adapted from MacKie) [7]. 
Skin type  
I Fair skinned Caucasians who burn easily and never tan 
II Fair skinned Caucasians who burn easily and tan slowly and with difficulty 
III Medium skinned Caucasians who burn rarely and tan relatively easy 
IV Darker skinned Caucasians who virtually never burn and tan readily, e.g. some 
individuals with Mediterranean ancestry 
V Asian or Indian skin 
VI Afro-Caribbean or Black skin 
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ULTRAVIOLET RADIATION  
 
UVR is a type of electromagnetic radiation. 
Electromagnetic radiation is a stream of photons, which are massless particles in a 
wave-like pattern which move at the speed of light [8]. 
It can be divided into cosmic rays, gamma rays, X-rays, UVR, visible light, micro 
waves and radio waves. The photons of a radio wave contain less energy than the 
photons of UVR or gamma rays. The more energy a photon has, the more damage it 
can cause to cells. The spectrum of electromagnetic wavelengths is shown 
schematically in Figure 3. 
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Figure 3 The electromagnetic spectrum. 
 
 
 
The German physicist Johann Ritter (1776-1810) is credited with the discovery of 
UVR in 1801. This was done soon after the discovery of infrared light. Ritter found 
that there exist invisible rays from the sun that efficiently darken silver chloride, 
namely UVR [9]. 
In 1893 the Danish dermatologist, Niels Finsen (1860-1904) introduced phototherapy 
against lupus vulgaris with good results. In 1903, one year before his death, he was 
awarded the Nobel Prize in medicine with the motivation "in recognition of his 
contribution to the treatment of diseases, especially lupus vulgaris, with concentrated 
light radiation, whereby he has opened a new avenue for medical science" [10, 11]. 
 
Normally the UVR is divided into three groups; UVA, UVB and UVC. In 1932 this 
division was introduced by the International Commission on Illumination (CIE) [12]: 
 
UVA (315-400 nm) 
UVB (280-315 nm) 
UVC (200-280 nm) 
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However, it is more common to use a slightly different division: 
 
UVA (320-400 nm) 
UVB (290-320 nm) 
UVC (200-290 nm) 
 
The division between UVB and UVC is set at 290 nm since it is unlikely that 
wavelengths below 290 nm reach the Earth. The division between UVB and UVA is 
perhaps more arbitrary [13]. 
In the literature one can also see a division of UVA into UVA1 (340-400 nm) and 
UVA2 (320-340 nm). 
 
The sun is the largest source of UVR. The ozone layer limits the amount of UV that 
reaches the Earth’s surface. UVC is completely filtered by the ozone layer, but we 
can encounter it from artificial sources such as welding equipment. 
About 6% of the UVR that reaches the Earth is UVB and the rest is UVA. The amount 
of UVR reaching the surface is influenced by the solar zenith angle which varies with 
time of day and year. The thickness of the ozone layer and the altitude also 
influences the amount of UVR that reaches the Earth. A person situated at a higher 
altitude would have more of the atmosphere is below herself, and the atmosphere will 
also be thinner. 
 
The UV dose that gives a barely noticeable erythema is called the Minimal Erythemal 
Dose (MED). This dose is in fact individual, and has to be specified in each case but 
it is nevertheless used to describe doses of about 200-300 J/m2. The standard 
erythema dose (SED) is better to use, where 1 SED equals 100 J/m2 erythema-
weighted UVR [14]. 
 
UV Index 
The UV Index was developed in the 1990s by WHO in collaboration with several  
other organizations. The UV Index provides information about the UVR level to help 
us plan outdoor activities in order to prevent overexposure to UVR [15]. 
The definition is:  
 
∫= 400
250
)( λλλ dSEkI ererUV  
 
where Eλ= solar spectral irradiance in Wm-2nm-1; dλ= wavelength interval used in the 
summation; Ser(λ)= erythema reference action spectrum; ker= a constant equal to  
40 m2W-1. 
 
The UV Index is normally reported along with the weather forecast in newspapers, on 
TV and/or on radio. In Sweden the UV Index is measured by the Swedish 
Meteorological and Hydrological Institute (SMHI) and is normally displayed in the 
newspapers during summer. On the website of SMHI the current UV Index in 
Sweden is reported the entire year. Table 2 shows how the UV Index normally is 
reported.  
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During summer in Sweden, the UV Index is usually between 4 to7, and during winter 
below 2.The UV Index varies with the factors mentioned in the previous section about 
UVR [16]. 
 
Table 2 UV Index 
Category UV Index range 
Low 0-2 
Moderate 3-5 
High 6-7 
Very High 8-10 
Extreme ≥11 
 
 
 
Disorders linked to UV radiation 
The World Health Organization (WHO) has listed nine diseases with a strong causal 
relationship to excessive UVR exposure and three diseases due to under-exposure 
to UVR. The diseases linked to over-exposure are the three most common types of 
skin cancer, actinic keratosis (AK), sunburn, cortical cataract, pterygium, reactivation 
of herpes labialis and squamous cell carcinoma (SCC) of the cornea and conjunctiva. 
The diseases linked to under-exposure are rickets, osteomalacia and osteoporosis. 
These diseases are all connected with vitamin D, which is produced in the skin after 
UV-exposure. Vitamin D plays an important role for our bone health. Low levels of 
vitamin D may be related to autoimmune diseases such as multiple sclerosis and 
type 1 diabetes. Deficiency of vitamin D may also have a relationship to certain 
cancers, e.g. prostate and non-Hodgkin lymphoma. The evidence is not yet 
convincing but in the future we may see a longer list of diseases with a strong causal 
relationship due to under-exposure to UVR [17]. 
 
Skin cancer 
It has been known for a long time that UVR can cause skin cancer [18]. UVB can 
cause DNA damage which leads to the development of skin cancer [19]. One 
common type of DNA injury is the formation of pyrimidine dimers. This is normally 
repaired by the enzymes, exonuclease, DNA polymerase and ligase, which excise 
the damaged DNA and rebuild it to normal DNA. However, this is not 100% effective 
and sometimes the repair mechanism fails, which can lead to the development of 
skin cancer. In the rare disorder Xeroderma pigmentosum, the patients lack the 
enzymes to repair the DNA. They must be extremely careful not to expose 
themselves to UVR; otherwise they will develop skin cancer at a very young age [20]. 
Other forms of DNA-damage can also occur such as single strand breaks and DNA 
crosslinks. UVA can have an indirect DNA-damaging potential through the production 
of free radicals, which causes oxidative stress. 
 
There are three major types of skin cancer: cutaneous malignant melanoma (CMM), 
SCC, and basal cell carcinoma (BCC). SCC and BCC are generally called non-
melanoma skin cancers (NMSC). NMSC are rarely lethal but can cause severe 
disfiguration, and they contribute to the economic burden of the health care system. 
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In Sweden during 2004, 3,420 new cases of SCC were registered, and the estimated 
number of new cases of BCC was 36,500. Until 2003 there has not been a register in 
Sweden for BCC. It is the Pathology and Cytology departments which report the 
BCCs [21]; hence there might be an underestimation since BCCs are commonly 
treated without a histopathological diagnosis. For CMM, the most serious type of skin 
cancer,1,950 new cases were registered in Sweden during 2004. The number of 
deaths in Sweden during 2002 was 380 due to CMM and 63 due to NMSC [22]. 
There are also precancerous lesions such as AK and SCC in situ (synonym Bowen’s 
disease) which can develop into invasive SCC.  
There are several articles that show a causal relationship of UVB with AK and SCC 
[19, 23, 24]. Which wavelengths are primarily the cause of BCC is still not known 
[25]. For CMM, there are studies supporting both UVA and UVB as the main cause. It 
seems that mutations in the tumour suppressor gene CDKN2A and in the oncogenes 
N-ras and H-ras are the most important cause for developing CMM and that UVR 
may have a major role in inducing these mutations although the action spectrum is 
still unknown [26]. Setlow et al. showed in a fish model that it was mainly UVA that 
was responsible for the induction of CMM [27], and other studies support that 
hypothesis [28, 29], while de Fabo et al. showed in a mouse model that only UVB 
initiated CMM [30].  
 
Probably the truth is somewhere in between. Both UVA and UVB can damage DNA. 
It is important to remember that there is an interplay between UVR and other factors, 
e.g. skin type and number of nevi. 
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SUNSCREENS 
General aspects 
Protection against the sun has been important as long as there been life on Earth. In 
the early days people probably used clay or different ointments to put on the skin, 
and the shade from trees and buildings was presumably also used. 
 
For a long time, pale skin was an ideal. It showed that one did not have to work 
outdoors in the fields. The women protected themselves with broad-brimmed hats 
and parasols. 
 
In the 1920s the ideal changed. This is usually ascribed to Coco Chanel (1883-1971), 
the legendary fashion designer. The story says that she returned from a Palm Beach 
vacation with a suntan, and all of a sudden it was very fashionable to be tanned. This 
coincides with the development of the Industrial Revolution when many people 
worked in the factories, away from the sun. Now a suntan declared that one had time 
to be outdoors, sailing, travelling etc. [31, 32].  
The first commercial sunscreens appeared in the 1920s and 1930s and the most 
successful was Ambre Solaire containing benzyl salicylate, prepared by Scheuller, 
who founded the company known as l’Oréal [33]. These sunscreens gave good 
protection against erythema. 
 
During World War (WW) II, sunscreens were further developed by US government-
sponsored programmes. Sunscreens were used to protect the American soldiers 
fighting in the Pacific [34]. Chemicals like red petrolatum and salicylates were used 
[35]. Red petrolatum is a product of the process of refining crude oil to gasoline and 
oil. It was used for veterinary purposes. Its red color is believed to be due to an 
aromatic hydrocarbon [36]. The sun-protecting properties of red petrolatum were in 
fact known prior to WW II. Urbach describes in an article that his father used red 
petrolatum during WW I to protect the hands from sunburn [33]. 
 
After WW II, sunscreens became more widespread and also more popular to a lot of 
consumers. During this period it was more common to go on vacation and spend the 
holiday at the beach. A golden suntan was equivalent to good health. Para-
aminobenzoate (PABA) was introduced as a sunscreen, giving its UV-protecting 
properties in the UVB area, first as a prescription drug, but later as an over-the-
counter preparation [37, 38]. Allergy to PABA started to be reported and by the late 
1980s it was rare to find PABA in sunscreens. Commercials stated that their products 
were “PABA-free”. PABA-esters are still used and they seem to be less prone to 
induce contact allergies [39]. 
 
In the 1980s benzophenone-3 (BZ-3) was introduced and it soon became very 
popular. BZ-3 gives good protection also in the UVA range. However, BZ-3 is a 
common photocontatct allergen [40] and there have been reports about 
percutaneous absorption and a possible hormone effect [41]. Products with BZ-3 are 
no longer sold at Swedish pharmacies. Sunscreens are incorporated in many other 
cosmetic products such as hair spray, face creams and make-up. They are also used 
to protect e.g. paint from UV degradation. 
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Sunscreens can be divided into organic chemical absorbers and inorganic chemical 
absorbers. The protective properties of the sunscreen can be due to absorbing and/ 
or scattering effects. The organic chemical absorbers have reactive structures that 
can take up the energy from UVR and then go back to a relaxed state by sending out 
the energy as heat. They can be classified into different groups, based on their 
chemical structure: cinnamates, PABA derivates, salicylates, benzophenones, 
camphor derivates, dibenzoylmethanes, anthranilates and miscellaneous (Figure 4, 
p.12) [42]. Table 3 shows the ingredients approved for use in Europe. Inorganic 
chemical absorbers both scatter and absorb UVR. They consist of nanoparticles of 
titanium dioxide (TiO2) and zinc oxide (ZnO).  
 
   
     
 
Table 3 Chemical UVR absorbers approved for use in Europe (adapted from IARC Handbook of sunscreens) [43]. 
INCI name CAS no Systematic name*  
Organic chemical absorbers 
UVB absorbers 
Cinnamates   
Ethylhexyl methoxycinnamate 5466-77-3 2-Ethylhexyl 4-methoxycinnamate 
Isoamyl-para-methoxycinnamate 71617-10-2 2-Propenoic acid, 3-(4-methoxyphenyl)-, 3-methylbutyl ester 
   
para-Aminobenzoic acids (PABAs)   
Ethylhexyl dimethyl PABA 21245-02-3 Benzoic acid, 4-(dimethylamino)-, 2-ethylhexyl ester 
PABA 150-13-0 Benzoic acid, 4-amino- 
PEG-25 PABA 
 
116242-27-4 
 
Poly(oxy-1,2-ethanediyl), alpha,alpha'-(((4-carboxyphenyl)imino)di-2,1-ethanediyl)bis(omega-
hydroxy-, ester with alpha-hydro-omega-hydroxypoly(oxy-1,2-ethanediyl) (1:1) 
   
Salicylates   
Ethylhexyl salicylate 118-60-5 Benzoic acid, 2-hydroxy-, 2-ethylhexyl ester 
Homosalate 118-56-9 Benzoic acid, 2-hydroxy-, 3,3,5-trimethylcyclohexyl ester 
   
Camphor derivates   
3-Benzylidene camphor 15087-24-8 Bicyclo[2.2.1]heptan-2-one, 1,7,7-trimethyl-3-(phenylmethylene)- 
Benzylidene camphor sulfonic acid 
 
56039-58-8 
 
Benzenesulfonic acid, 4-((4,7,7-trimethyl-3-oxobicyclo(2.2.1)hept-2-ylidene)methyl)- 
Camphor benzalkonium methosulfate 
 
52793-97-2 
 
Benzenaminium, N,N,N-trimethyl-4-[(4,7,7-trimethyl-3-oxobicyclo[2.2.1]hept-2-ylidene)methyl]-, 
methyl sulfate 
4-Methylbenzylidene camphor 36861-47-9 Bicyclo[2.2.1]heptan-2-one, 1,7,7-trimethyl-3-[(4-methylphenyl)methylene]- 
Polyacrylamidomethyl benzylidene 
camphor 
113783-61-2 
 
 
   
Miscellaneous   
Diethylhexylbutamido triazone 154702-15-5 Benzoic acid, 4,4'-[[6-[[4-[[(1,1-dimethylethyl)amino]carbonyl]phenyl]amino]-1,3,5-triazine-2,4-
diyl]diimino]bis-, bis(2-ethylhexyl) ester 
Ethylhexyl triazone 88122-99-0 Benzoic acid, 4,4',4''-(1,3,5-triazine-2,4,6-triyltriimino)tris-, tris(2-ethylhexyl) ester 
Octocrylene 6197-30-4 2-Propenoic acid, 2-cyano-3,3-diphenyl-, 2-ethylhexyl ester 
Phenylbenzimidazole sulfonic acid 27503-81-7 1H-Benzimidazole-5-sulfonic acid, 2-phenyl- 
 
 
   
     
 
Table 3 cont 
UVA absorbers CAS no Systematic name* 
Benzophenones   
Benzophenone-3 131-57-7 Methanone, (2-hydroxy-4-methoxyphenyl)phenyl- 
Benzophenone-4 4065-45-6 Benzenesulfonic acid, 5-benzoyl-4-hydroxy-2-methoxy- 
Benzophenone-5 6628-37-1 Benzenesulfonic acid, 5-benzoyl-4-hydroxy-2-methoxy-, monosodium salt 
   
Camphor derivates   
Terephthalylidene dicamphor sulfonic acid 90457-82-2 Bicyclo [2.2.1] heptane-1-methanesulfonic acid, 3,3'-(1,4-phenylenedimethylidene) bis(7,7-
dimethyl-2-oxo-** 
   
Dibenzoylmethane   
Butyl methoxydibenzoylmethane 70356-09-1 1,3-Propanedione, 1-[4-(1,1-dimethylethyl)phenyl]-3-(4-methoxyphenyl)- 
   
Miscellaneous   
Bisymidazylate (proposed name) 180898-37-7 1H-Benzimidazole-4,6-disulfonic acid, 2,2'-(1,4-phenylene)bis-, disodium salt 
   
UVA and UVB absorbers   
Miscellaneous   
Anisotriazine (proposed name) 187393-00-6 Phenol, 2,2'-[6-(4-methoxyphenyl)-1,3,5-triazine-2,4-diyl]bis[5-[(2-ethylhexyl)oxy]- 
Drometrizole trisiloxane 155633-54-8  
Methylene-bis-benzotriazolyl 
tetramethylbutylphenol 
103597-45-1 
 
Phenol, 2,2'-methylenebis(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)- 
   
Inorganic chemical absorbers   
Titanium dioxide 13463-67-7  
Zinc oxide 1314-13-2  
INCI International Nomenclature of Cosmetic Ingredients 
CAS Chemical Abstracts Service 
* preferred by Swedish Chemicals Inspectorate [44]. 
** from ChemIDplus [45]. 
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Figure 4 Chemical structure of the seven groups of organic chemical sunscreens. 
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Benzophenone-3 
Benzophenones belong to the aromatic ketone category. They can absorb longer 
wavelengths, so they give good protection also in the UVA region [42]. They have 
been used since the 1980s and BZ-3 is the most common compound in the 
benzophenone group to use for sun protection. It has the molecular weight 228.26 
with melting point 66.5°C. 
 
 
O
OHO
CH3
 
 
Figure 5 The structure of BZ-3. 
 
 
 
Sunscreens and skin cancer 
Sunscreens were mainly designed to protect against erythema. There have been 
studies which indicate that sunscreens increase the risk of getting CMM [46, 47], but 
other studies report the opposite [48]. Two review articles about sunscreens 
conclude that there is no relation between sunscreen use and a higher risk of getting 
CMM [49, 50]. Some studies support the idea that sunscreens are able to protect 
against skin cancer and actinic keratosis, but there was no evidence that sunscreens 
were protecting against BCC or CMM [51, 52]. 
 
One error which people may make when they use sunscreens is that they stay longer 
in the sun than if they had not used a sunscreen [53]. 
Another common error is that the majority of users do not use the recommended 
amount, 2 mg/cm2, necessary to obtain the sun protection factor (SPF) value marked 
on the bottle. Studies show that the average applied amount is much lower, 0.5 to 1.0 
mg/cm2 [54, 55]. Patients with the light-induced skin disease called polymorphic light 
eruption (a group that is very motivated to obtain good sunprotection) used on 
average 0.5 mg/cm2; they also applied the lotion in an uneven manner [56]. 
Education made the patients use more sunscreen, on average 1.13 mg/cm2, still too 
low to obtain the SPF value [57]. 
 
Adverse effects of sunscreens 
There have been concerns about pulmonary effects of TiO2 after inhalation. If the 
TiO2 particles are too large, the cream will appear white on the skin. For that reason, 
nanoparticles of TiO2 are used in sunscreens to make them cosmetically appealing. 
One study has shown a species difference after inhalation of TiO2,  rats had a 
marked progression of histopathological lesions while hamsters and mice did not 
[58]. Boffetta et al. studied 15,017 workers in the TiO2 industry in Europe. They did 
not find any carcinogenic effect of TiO2 dust on the human lung [59].
 
SUNSCREENS    
14 
 
Schlumpf et al. reported endocrine activity of several sunscreens. They found 
estrogenic influence on rats after ingestion of the sunscreen compounds 4-methyl-
benzylidene camphor (MBC), ethylhexyl methoxycinnamate (EHMC), and BZ-3. After 
dermal exposure to rats, MBC gave an increased uterine weight [41, 60]. The rats 
were exposed to quite large amounts of the substances. One study showed that BZ-3 
and its metabolites, dihydroxy methoxybenzophenone (DHMB) and trihydroxy 
benzophenone (THB), could have estrogenic effects on MCF-human breast cancer 
cells [61]. However, another study on humans did not show any endocrine effect after 
dermal exposure to sunscreens [62] and the European Commission concluded in a 
plenary meeting in 2001 that sunscreens do not have an estrogenic effect which 
could potentially affect human health [63]. 
 
The environment may also be affected by the use of sunscreens. TiO2 can have 
ecotoxic effects on algae and daphnids [64]. Octocrylene and MBC have been found 
in fish from Swiss rivers [65] and those compounds together with BZ-3, EHMC and 
butyl methoxydibenzoylmethane (BMDBM) have been found in Swiss lakes with a 
higher concentration during summer. The investigated lakes were used for 
recreational activities and the sunscreens probably originated from swimmers who 
had used a sunscreen [66]. 
 
Skin problems 
Subjective irritation 
This is among the most frequent complaints. The symptoms can be stinging, burning 
and/or itching without any visible skin signs [67]. 
 
Contact and photocontact dermatitis 
Contact and photocontact dermatitis can be caused by sunscreens. These can be 
both irritant and allergic reactions. BZ-3, isopropyl dibenzoylmethane and BMDBM 
were the most common sensitizers in a Swedish study [40]. PABA used to be a 
common sensitizer, but PABA is practically no longer used and the PABA-esters 
seem to have less sensitizing properties [39]. There are also reports of contact 
urticaria, erythema multiforme and anaphylactic shock due to BZ-3 [68-70]. 
 
Sensitization from TiO2 and ZnO is practically non-existent. 
 
Percutaneous absorption 
It has long been known that the skin is permeable to different substances, even 
though we sometimes tend to forget this. 
In 1886, over a century ago, there were several cases of cyanosis in newborn 
children due to aniline toxicity. The diapers were stamped with a 4½ inch oval and 
the infants who received a newly stamped diaper became cyanotic due to the 
percutaneous transfer of aniline [71]. 
 
There have been lethal outcomes for children when they have been in skin contact 
with hexachlorophene, an antibacterial substance, but also a known neurotoxin [72, 
73]. 
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Several reports of poisoning after topical application of salicylate, some fatal, have 
also been published. The list of substances that can give systemic effects when 
applied topically can be much longer [74, 75]. 
 
For sunscreens, several studies about percutaneous absorption are available. One of 
the first studies was conducted in 1970 when 21 organic compounds, among them 
the sunscreen PABA, were investigated. Carbon14 labeled compounds were applied 
on the forearm and measured in urine. Almost 30% of the applied isotope was 
present in the urine five days after the application of isotope-labeled PABA [76]. 
BZ-3 is one of the most bioavailable photoactive compound following dermal 
application [77]. Between 0.5-9% of applied dose BZ-3 penetrates the skin [78-82]. 
BZ-3 is extensively conjugated and the main excretion path in rat is urine. This does 
not mean that BZ-3 has toxicological properties during normal use, but it raises 
questions about possible toxicological endpoints [77, 83]. 
 
Methods for measurement of percutaneous absorption 
There are several methods to measure in-vivo absorption. Like all in-vivo methods, 
they have the advantage of being more true to a real-life situation. Negative aspects 
are that they are usually more expensive and that people or animals have to be 
exposed to the compounds. In-vitro methods are more easily controlled but cannot 
account for processes in the body. Table 4 summarizes the advantages and 
disadvantages. Some common methods are described in summary. 
 
 
Table 4 Advantages and disadvantages for in-vivo and in-vitro methods. 
 Advantages Disadvantages 
In vivo Biological response Exposure to humans/animals 
  Expensive 
In vitro Less expensive No biological endpoint 
 Less risk for humans/animals  
 Reproducible  
 
 
 
In-vivo methods for absorption measurements [84] 
Radioactivity in blood or excreta 
The radioactivity in blood or excreta can be measured after topical application of a 
labeled compound. It is common to use carbon14 or tritium. This method does not 
take into consideration that the compound can be metabolized. 
Stripping method 
The compound is applied to the skin. After a certain time (usually 30 min) the stratum 
corneum is removed by tape application and removal. The tape strippings are 
assayed with e.g. an HPLC method. 
Absolute topical bioavailability 
The compound is measured specifically in blood, urine and/or faeces. 
 
Animals can also be used as a model but sometimes animal skin is more permeable 
than human skin. 
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In-vitro method for absorption measurements [85] 
Diffusion cell 
Diffusion cells can be used. They consist of a donor and a receptor chamber with a 
membrane placed in between. The compounds of interest are dissolved in an 
appropriate fluid and passed through the chambers. The membrane can consist of 
human skin, animal skin or an artificial material. 
 
SPF testing 
The sun protection factor (SPF) has been used since the 1930s [86]. During the 
decades some changes have been made, and there were some differences between 
countries. Since 2002, the European cosmetic toiletry and perfume association 
(COLIPA), Japan Cosmetic Industry Association (JCIA) and Cosmetic, Toiletry and 
Fragrance Association of South Africa (CTFA-SA) decided on a joint agreement 
regarding the international SPF test method [87]. This method is applied worldwide 
but there are disparities in e.g. protocols, leading to slight differences. 
The method in summary is as follows. A test panel of subjects with skin types I, II and 
III according to Fitzpatrick is included. The back is used as test area, and the area 
should be between 30 cm2 and 60 cm2. A xenon arc lamp with an output in the 
wavelength region between 290 and 400 nm is used. The applied amount of product 
should be 2.00 mg/cm2. The product should be deposited with a syringe and spread 
with light pressure, using a finger cot. This applies to lotions, liquids, milks, creams 
and sprays. Exposure to UVR should start 15 to 30 min after the application. The 
individual MED (MEDi) is calculated, both for unprotected skin (MEDui) and for 
protected skin (MEDpi). The individual SPF is the ratio of the MEDpi and MEDui. 
 
SPFi = 
 
 
The SPF for the product is calculated as the arithmetic mean of all valid SPFi 
obtained.  
 
Since the endpoint is erythema, it is mainly the UVB protection that is measured with 
the SPF method.  
 
UVA testing 
In contrast to the SPF method, there is no standard method that is used worldwide 
for UVA testing or labeling. For UVA there is no clearly defined endpoint as erythema 
is for UVB. 
Several different methods are used, and sometimes a combination of methods. 
Which method is used differs between continents, countries and companies; no 
consensus so far exists on the laboratory measurements. The most frequently used 
methods are explained in summary. 
 
 
MEDpi 
MEDui 
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In-vivo methods 
The “protection factor UVA” (PFA) [88] 
A test panel of subjects, (Fitzpatrick’s skin type I to III), receive doses of UVA from a 
xenon arc lamp with the output between 320 to 400 nm. The minimal response dose 
(MRD) was measured with protection (MRDp) and without protection (MRDu) with the 
endpoint minimal erythema or tanning. The MRDp was assessed 16 to 24 h after 
UVA exposure. The applied amount of sunscreen was 2 mg/cm2. 
 
PFA = 
 
Persistent pigment darkening (PPD) [89] 
PPD is a photooxidation of melanin or precursors causing a color change of the skin. 
A test panel of subjects (Fitzpatrick’s skin types II to IV) receive doses of UVA from a 
xenon arc lamp with an output between 320 to 400 nm. The minimal pigmenting dose 
(MPD) was established. The MPD with protection (MPDp) and without protection 
(MPDu) were measured. The applied amount of sunscreen was 2 mg/cm2. The 
MPDp was assessed 3±1 hour after UVA exposure. 
 
UVA protection factor =  
 
 
The UVA protection factor (UVA-PF) is the arithmetic mean of the UVA-PFi values 
obtained from at least 10 subjects. PFA and PPD are basically the same method but 
differ slightly. In the PFA method, the endpoint is tanning or erythema and in PPD the 
endpoint is tanning solely. PPD excludes people with skin type I and PFA excludes 
people with skin type IV [77, 90, 91]. 
 
It also exists methods using immediate pigment darkening and measurements on 
sensitized skin [92, 93]. 
 
In-vitro methods 
Critical Wavelength [94] 
This is a method developed by Diffey and Robson, using thin-film substrate 
spectrophotometry. The definition of the critical wavelength (λc) is the wavelength at 
which the integral of the spectral absorbance curve reaches 90% of the integral from 
290 to 400 nm.  
 
( )∫ =Αc dλ λλ
290
9.0 ( )∫ Α400
290
λλ d  
 
where A=absorption; dλ= wavelength interval used in the summation.
MRDp 
MRDu 
MPDp 
MPDu 
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The UVA/UVB-ratio [95] 
This method is based on the critical wavelength method to calculate the ratio of UVA 
(320 to 400 nm) and UVB (290-320 nm). 
 
∫∫
∫∫
320
290
320
290
400
320
400
320
)(
)(
λλλ
λλλ
ddA
ddA
 
 
where A=absorption; dλ= wavelength interval used in the summation. 
 
Australian standard/New Zealand standard [96] 
There are three alternative methods which can be used depending on the type of 
sunscreen being tested. In all three a spectrophotometer is used. The transmission is 
measured in the region 320 nm to 360 nm. If method (a) or (b) is used, maximum 
10% of the light may be transmitted and for method (c) maximum 1% of the light may 
be transmitted, in order to call the product broad-spectrum.  
 
a) solution method 
The product is dissolved into a spectroscopic grade solvent and put in a quartz 
cell. The percentage transmission is calculated.  
b) thin film method 
This method is used when the product is rather opaque. The product is filled in a 
quartz cell, constructed to provide an 8 μm thick layer of the sunscreen. The 
percentage transmission is calculated. 
c) plate method 
The sunscreen is applied to one surface of a quartz plate in a 20 μm thick layer 
(which corresponds to 2.0 mg/cm2. The percentage transmission is calculated. 
 
Labeling in different countries 
Japan uses the in-vivo PPD method and the products are marked PA+, PA++ or 
PA+++. 
In Europe no method is adopted officially, so the labeling differs between countries 
and between brands in the same country. 
 
In the UK it is common to use the Boots star rating system based on the UVA/UVB-
ratio (Table 5). 
 
Table 5 The Boots star rating system. 
UVA/UVB-ratio Stars Category
0.0 to 0.2 no rating  
0.21 to 0.4 one star minimum 
0.41 to 0.6 two stars moderate 
0.61 to 0.8 three stars good 
0.81 to 0.9 four stars superior 
>0.91 five stars ultra 
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According to the US Food and Drug Administration (FDA) there is no approved rating 
system that identifies UVA protection. Scientists are working to create a standardized 
testing system to measure UVA protection [97]. 
 
Protection by clothing 
Clothes are widely recommended as UV protection, and they give good protection, 
but there are some pitfalls. Loosely woven fabrics do not protect as well as tightly 
woven fabrics and wet material gives poorer protection than dry textiles. [98] There 
are several reports about the protection factor for clothes [99, 100]. 
For clothes, the ultraviolet protection factor (UPF) is normally used. There are 
different test methods for determination of the UPF, such as in-vivo methods similar 
to the SPF testing, but the most frequently is an in-vitro method using a 
spectrophotometer. Samples of the fabric are cut out and placed in the 
spectrophotometer set for 290 to 400 nm. 
 
The definition is [101]: 
 
UPF = 
∑ Δ
Δ∑
400
290
400
290
λ
λ
λλλ
λλ
TSE
SE
 
 
where Eλ= the solar spectral irradiance in Wm-2nm-1; Sλ = the relative erythemal 
spectral effectiveness ; Tλ=spectral transmission coefficient of the textile material; 
∆λ= the bandwidth in nm; λ = the wavelength in nm.  
 
There are several brands that manufacture specially designed UV-protecting clothes 
with UPF 50+. 
Sun protection for animals and plants 
It is not only humans that are affected by UVR: animals and plants are also 
concerned. For example, fair-skinned pigs can be sunburnt. Some plants have 
developed a strategy using flavonoids to become more pigmented, they also may 
have enzymes which can perform DNA repair. Cyanobacteria are one of the first 
existing life forms on earth; they contain UV-absorbing pigments, mycosporinelike 
amino acids [102]. 
 
The hippopotamus excretes a fluid that contains a pigment which at first is red and 
then turns brown. The function of this is not fully understood, but the fluid has both 
antibiotic and UV-absorbing properties [103]. 
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HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY 
High-performance liquid chromatography (HPLC) was first developed around 1900 
by the Russian botanist Michail Tsvet (1872-1919). He used it to separate different 
plant colors, such as chlorophyll. In the 1940s the method was rediscovered and 
further developed by the British chemists Archer JP Martin (1910-2002) and Richard 
Synge (1914-1994) who received the Nobel Prize for their achievements in 1952 [1, 
104]. Since the 1970s, HPLC has been used to separate different chemical 
compounds. A mobile phase is forced with high pressure through a stationary phase, 
a column. The sample is injected and the solution goes through the stationary phase. 
The different components go through the column at different speeds and are then 
separated. 
Normally a UV detector with variable wavelength is used. The detector registers each 
component as a peak in a graph called a chromatogram. 
 
 
 
 
Figure 6 Schematic picture of HPLC [105]. 
 
 
Usually a reverse-phase HPLC is used; the stationary phase is nonpolar 
(hydrophobic), and the mobile phase is a polar liquid, such as mixtures of water and 
methanol or water and acetonitrile. In our set-up we used a reverse-phase HPLC. 
Detectors with infrared light, fluorescence or mass spectrometry can also be used. 
There have been several studies about sunscreens and HPLC [106-109]. However, 
few of them dealt with human urine and none of them suited our purpose completely. 
In Table 6 an overview of studies about BZ-3 in biological materials is presented. 
Only studies with detailed information about the analytical set-up have been included. 
Some studies dealt with the issue but did not provide sufficient information to 
reproduce their experimental set-up. 
     
 
 
 
 
 
 
 
 
 
Table 6 An overview of studies about BZ-3 (and its metabolites) and HPLC, applied on biological samples. Dermal exposure unless otherwise mentioned. 
None of the methods used an internal standard. 
reference compound minimum 
detectable 
limit 
biological sample mobile phase column hydrolysis wavelength comment 
Abdel-Nabi et 
al. 
(1992) [110] 
BZ-3 2.0 ng/ml urine 
blood 
tissue*** 
methanol:acetic 
acid (60:40) 
Hypersil 
ODS C18 
β-
glucuronidase 
HCl 
305 rat, oral 
exposure 
Jiang et al. 
(1996) [111] 
BZ-3* 
 
0.05 μg/ml spiked plasma methanol-water 
(88:12) 
Novapak 
C18 RCM 
 315 human 
 
Potard et al. 
(1999) [107] 
BZ-3* 20 μg/ml skin tissue methanol:water 
(69:31) 
Novapak 
C18 
 291 human 
Sarvieya et al. 
(2004) [81] 
BZ-3* 
DHB** 
THB** 
0.8 ng 
(0.08μg/ml) 
spiked samples 
(urine,skin 
tissue,plasma) 
urine, skin tissue, 
plasma 
methanol-water 
gradient 
75:25-92:8 
Symmetry 
C18 
β-
glucuronidase 
 
289 human 
Kasichayanula  
et al. 
(2005) [112] 
BZ-3 
DHB 
THB 
DHMB 
BZ-3 0.5 ng 
DHB 0.7 ng 
THB 0.5 ng 
DHMB 0.6 ng 
plasma 
urine 
skin tissue 
methanol:water 
gradient(50:50-
90:10) 
Milford C18  289 piglet 
* Other compounds were also investigated. 
** Only trace amounts were found.  
*** Liver, kidney and testes. 
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SPECTROPHOTOMETER  
A spectrophotometer is used to measure the absorption of electromagnetic radiation 
at different wavelengths. It consists of two instruments, a spectrometer that produces 
light of a selected wavelength and a photometer to measure the intensity of light. 
It is mainly used to measure the absorbance of a substance at different wavelengths 
but also to determine the concentration of a compound by using the Lambert-Beer 
law [9]. 
 
 
 
Figure 7 A spectrophotometer [113]. 
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AIMS OF THE STUDY 
Paper I 
To investigate the excretion of BZ-3 in urine after one whole-body application of a 
sunscreen containing 4% BZ-3. 
 
Paper II 
To examine the excretion of BZ-3 in urine after repeated whole-body applications of a 
sunscreen containing 4% BZ-3, and to investigate whether UVR had any impact on 
the excretion. 
 
Paper III 
To develop and validate a reverse-phase HPLC method to determine the amounts of 
BZ-3 and DHB in human urine. The assay was applied to study the urinary excretion 
pattern of BZ-3 and DHB after repeated whole-body applications of a commercial 
sunscreen. 
 
Paper IV 
To examine the photostability of seven commercial sunscreens before and after 
exposure to artificial UVR and before and after exposure to UVR from the sun. 
 
 
 
 
    
24 
MATERIAL AND METHODS 
 
Paper I 
The study was performed on 11 volunteers (mean age 26 years, range 22-37 years, 
4 women, 7 men). They provided a reference urine sample prior to the application of 
the sunscreen. 
They applied a commercially available sun-protecting lotion containing 4% BZ-3 over 
the whole body except the scalp and genital area. Urine samples were collected 
during a 48-hour period after the application. They used the recommended amount 2 
mg/cm2 and the body surface area (BSA) was estimated to be 2 m2. BZ-3 in urine 
was analyzed with a reverse-phase HPLC method. 
 
Paper II 
The study was performed on 25 healthy participants (mean age 27, range 22-42 
years, 16 women, 9 men). They provided a reference urine sample prior to the first 
application of the sunscreen. They applied 2 mg/cm2 of a commercially available sun- 
protecting lotion containing 4% BZ-3, morning and night for five days. The sunscreen 
was distributed in plastic containers. The urine was measured during those five days 
and for a further five days after the last application. The individual BSA was 
calculated [114]; hence each participant applied a different amount of sunscreen. 
They were randomized into two groups: A and B (Table 7). One participant in Group 
A was excluded due to lack of compliance. 
 
 
 
Table 7 Demographics of volunteers in group A and B. 
Group Women Men Mean age 
(years) 
Range 
(years) 
A (n=11) 6 5 26 22-37 
B (n=14) 9 5 28 22-42 
 
 
 
Group A did not receive any UVR. Group B received UVR during the five days the 
sunscreen was applied, according to skin type: total amount UVA between 400 and 
707 J/cm2, and total amount UVB between 0.46 and 2.0 J/cm2. For UVA irradiation a 
Dermalight Ultra A1, equipped with six light tubes Dr Hönle 200 W (Martinsreid, 
Germany), was used. For UVB irradiation an Esshå Corona IV, equipped with 28 light 
tubes, Philips UVB TL 40 W/12 (Eindhoven, the Netherlands), was used. 
The BZ-3 in urine was analyzed with the reverse-phase HPLC method described in 
Paper III. 
 
Paper III  
Urine samples were analyzed regarding both conjugated/non-conjugated BZ-3 and 
conjugated/non-conjugated DHB since both BZ-3 and DHB are extensively 
conjugated in the body. In Figure 8 the structure of DHB is shown. Solid-phase 
extraction (SPE) with C8 columns was followed by reverse-phase HPLC. For 
separation a HIChrom C18 column was used with an acetonitrile-water mobile phase 
and the detector was set at 287 nm. An internal standard was used to provide a more 
correct determination of the amounts. 
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Figure 8 The structure of DHB. 
 
 
 
Paper IV 
Seven commercial sunscreens were studied with absorption spectroscopy. In Table 8 
an overview of the photoactive compounds is presented. Sunscreen product, 0.5 
mg/cm2, was placed between plates of silica. The area under the curve (AUC) in the 
spectrum was calculated for UVA (320-400 nm), UVA1 (340-400 nm), UVA2 (320-
340 nm) and UVB (290-320 nm) before (AUCbefore) and after (AUCafter) artificial UVA 
(980 kJ/m2) and artificial UVB (12 kJ/m2). If the AUC Index (AUCI) defined as 
AUCafter/AUCbefore, was higher than 0.80, the sunscreen was considered photostable.  
For UVA irradiation, a UVASUN 2000 (MUTZHAS, Germany) was used. The output 
was mainly between 340-400 nm. For UVB irradiation an Esshå Corona Mini 
(Sweden), equipped with 2 light tubes, Philips TL 12 20 W, was used. 
For natural UV the samples were placed horizontally outdoors when the weather was 
sunny. This was done in July in Gothenburg. Spectra were measured after 30 min, 
90 min and 120 min of natural UV exposure. 
 
The spectra were recorded by a Cary 4 spectophotometer (Varian, USA) and we 
received the natural UV doses from SMHI. 
 
 
 
Table 8 The photoactive compounds in the investigated sunscreens, CAS no and SPF of the product. 
Photoactive 
compound 
CAS no Mainly 
protection 
against 
Active ingredients in the seven investigated 
sunscreen products  
  UVA UVB 1 2 3 4 5 6 7 
EHMC 5466-77-3  x x x x     
MBC 36861-47-9  x   x x x   
EHT 88122-99-0  x        
OC 6197-30-4  x      x  
BMDBM 70356-09-1 x  x x x x x x  
BZ-3 131-57-7 x   x x     
TLDCSA 90457-82-2 x       x  
TiO2 13463-67-7  x   x x  x x 
ZnO 1314-13-2 x        x 
SPF    4 14 10 10 6 10 15 
CAS Chemical Abstracts Service  
EHMC ethylhexyl methoxycinnamate MBC 4-methylbenzylidene camphor  
EHT ethylhexyl triazone OC octocrylene BMDBM butyl methoxydibenzoylmethane  
BZ-3 benzophenone-3 TLDCSA terephthalylidene dicamphor sulfonic acid 
TiO2 titanium dioxide ZnO zinc oxide  
SPF Sun Protection Factor 
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Statistical methods 
Paper II  
Differences were compared with Student’s t-test. A p-value of less than 0.05 was 
considered to indicate statistical significance. 
Correlations were calculated using Pearson’s correlation coefficient.  
 
Paper III 
The minimum detectable limit was defined as three times the baseline noise level. 
The within-day and between-days precision was calculated as relative SD (RSD). 
RSD=(SD/mean) x 100. 
 
Ethics 
Papers I and II 
The regional ethical review board in Gothenburg approved the studies. 
The volunteers participated after informed consent was obtained from them. 
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RESULTS  
 
Paper I 
A single whole-body application of a sunscreen containing 4% BZ-3 resulted in 
excretion of BZ-3 in the urine. The average total amount excreted was 11 mg, 
median 9.8 mg, which is approximately 0.4% of the applied amount BZ-3. 
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Figure 9 Accumulated amount of BZ-3 (μg) recovered in urine during a 48-hour period after topical 
application to 11 human volunteers. Each line represents one volunteer. 
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Figure 10 Three different excretion profiles to illustrate the variation in excretion pattern between the 
volunteers. Each line represents one volunteer.
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Paper II 
Repeated whole-body applications of a sunscreen containing 4% BZ-3 resulted in a 
higher excretion of BZ-3 in urine. The mean amount was 3.7% (range 1.2-8.7%) of 
the total amount applied BZ-3. There was no significant difference between groups A 
and B (p <0.99). Figure 11 shows the individual urinary excretion of BZ-3 (%). 
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Figure 11 Urinary excretion of BZ-3 after 10 days. Range 1.2%-8.7% of the total 
amount applied. The mean value of 3.7% is shown as a horizontal line. 
 
 
Paper III 
The detection limits for BZ-3 and DHB were 0.01 µmol/l (0.1 ng) and 0.16 µmol/l  
(2 ng) respectively. RSD was less than 10% for BZ-3 and less than 13% for DHB. 
The assay was linear r2 >0.99. 
 
            mV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 Example of a chromatogram from person 8. Internal standard (IS).
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BZ-3 and DHB were extensively conjugated and only a smaller part was excreted in 
the non-conjugated form, mean value 5.9% and 8.8% respectively (Figure 13). 
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Figure 13 The relations between conjugated/non-conjugated BZ-3 and conjugated/non-
conjugated DHB. 
 
 
 
The excretion pattern varied among the human volunteers; we discerned different 
patterns among the individuals (Figure 14). 
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Figure 14 Example of excretion pattern of conjugated BZ-3 and DHB.
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Paper IV 
Three sunscreens were photounstable after exposure to natural UV, in the UVA 
range the AUCI was between 0.36 and 0.76. In the UVB range one of these 
sunscreens showed an AUCI of 0.63. Three sunscreens were photostable after 
natural UV irradiation, with AUCI >0.80. Five of the sunscreens were photostable in 
the UVB region after artificial UV exposure. The combination of EHMC and BMDBM 
was always unstable regardless of which other photoactive compound was included. 
Table 9 shows an overview of the AUCI of the investigated sunscreens, and Figure 
15 shows UV absorbance spectra for Sunscreen 1. 
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Figure 15 UV absorbance spectra of UVA photounstable Sunscreen1 (AUCI <0.80). Before and after 
natural UV exposure, and before and after artificial UV exposure. 
   
 
 
 
 
  
  
 
 
 
Table 9 An overview of the AUCI of the investigated sunscreens. 
Sunscreen After natural UV exposure After artificial UV exposure 
 UVA UVA1 UVA2 UVB UVA UVA1 UVA2 UVB 
 30 min 90 min 120 min 30 min 90 min 120 min 30 min 90 min 120 min 30min 90 min 120 min     
1 0.72 0.46 0.36 0.69 0.38 0.29 0.83 0.65 0.54 0.91 0.87 0.81 0.36 0.32 0.45 0.69 
2 0.84 0.76 0.75 0.83 0.69 0.67 0.86 0.92 0.97 0.86 0.92 0.97 0.63 0.53 0.88 0.89 
3 0.67 0.41 0.41 0.59 0.30 0.34 0.81 0.58 0.52 0.92 0.75 0.63 0.40 0.31 0.58 0.73 
4 0.92 0.86 0.87 0.91 0.85 0.83 0.94 0.91 0.91 0.95 0.93 0.95 0.72 0.69 0.81 0.83 
5 0.96 0.89 0.85 0.94 0.87 0.83 0.99 0.95 0.93 0.99 0.99 0.98 0.90 0.88 0.97 0.97 
6 0.98 0.94 0.94 0.97 0.93 0.93 0.98 0.96 0.97 0.99 0.99 1.00 0.85 0.82 0.92 1.00 
7   0.99*   1.00*   0.96*   0.92* 0.99 0.99 1.00 0.99 
The AUCI is defined as AUCafter/AUCbefore. The bold numbers show when AUCI is <0.80. 
* Sunscreen 7 was exposed to natural UV during 240 min. 
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DISCUSSION 
Methodological considerations 
Papers I and II 
There was no control that the volunteers applied all of the sunscreen they received. 
Follow-up questions were asked when the urine samples were delivered, to learn 
whether there had been any difficulties. The volunteers had to measure the volume 
of urine every time they urinated. Two persons in Paper II forgot to do this on one or 
two occasions. Since that would lead to an underestimation of excreted BZ-3, they 
were also included. One person in Paper II was excluded due to obstacles in 
following the instructions. 
 
In Paper II, half of the volunteers were exposed to UV. For practical reasons this was 
done at lunchtime but the applications were done morning and night. The general 
recommendation is to apply the sunscreen 15 to 20 min prior to UV exposure. The 
delay between application and UV exposure may have influenced the results.  
 
Paper III 
For the standard solutions, methanol/ultrafiltrated water was used instead of urine. 
We tried to do the standard solutions in urine but the BZ-3 precipitated in the high 
concentrations. THB had unstable properties and it was therefore not analyzed. 
A previous study has shown that THB was was found only in trace amounts in human 
urine [81]. 
 
Paper IV 
The absorbance was too high for proper measurements when the recommended 
amount of 2 mg/cm2 was applied, causing distortion in the absorption spectrum. For 
this reason a thinner layer was applied. 
The number of silica plates was limited, so we were not able to expose all the 
sunscreens to natural sunlight at the same time. Hence, the sunscreens were 
exposed to different amounts of natural UV. 
 
The spectrophotometer did not have an integrated sphere, but since we are 
interested in changes in the absorbance, the absence of an integrating sphere is not 
a major problem. 
General discussion 
Many of us encounter sunscreens every day. They are not only incorporated in 
products specifically designed to protect against UVR, but also contained inproducts 
such as day-creams, lipsticks and foundations. 
Percutaneous absorption of different sunscreen compounds is important to 
investigate in order to aquire more knowledge about how much of a compound is 
absorbed. It is also essential to remember that the metabolites of a product can have 
properties different from the parent compound. When a new drug is tested on the 
market this is taken into consideration, but when it comes to sunscreens this is not 
the case. 
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Several studies have reported that BZ-3 is absorbed by the skin [76, 78, 79, 81]. Our 
data (Paper I) show that, after one whole-body application of a sunscreen containing 
4% BZ-3, BZ-3 can be found in human urine up to 48 hours after application. The 
previous studies about BZ-3 and metabolism have been performed on rats, mice or 
cell cultures [61, 115, 116]. Since we did not know for how long BZ-3 was going to be 
excreted in the urine, we chose a 48-hour period which had been used in a previous 
study [78]. Four of the volunteers did not reach their reference value at the end of the 
study; they still excreted BZ-3 48 hours after the application. 
 
In our next study (Paper II) we investigated the absorption of BZ-3 after repeated 
whole-body applications of a sunscreen containing 4% BZ-3. This time, the urine 
collection was performed during the five days the sunscreen was applied with an 
additional five days after the last application. The time of investigation was more than 
twice as long as in Paper I. Now we saw that none of the participants reached their 
reference value at the end of the study. We did not see any statistically significant 
influence by UV exposure. This may be due to factors such as time of irradiation, 
mentioned previously. BZ-3 is quite photostable as indicated in Paper IV, this can 
also be part of the explanation why there was no difference between the groups. 
 
Most of the BZ-3 excreted in the urine was in the conjugated form; this is consistent 
with previous studies showing that BZ-3 undergoes extensive conjugation in the body 
[78, 115]. Strassburg et al. have studied the development aspects of human hepatic 
drug glucuronidation in young children and adults. Their findings showed that the 
hepatic glucuronidation activity in children under the age of 24 months was lower 
than for adults for several drugs. Even though BZ-3 was not included in their study, 
BZ-3 undergoes extensive conjugation and these findings may be relevant for BZ-3 
as well. The development of hepatic glucuronidation enzymes is significant for the 
prevention of adverse drug effects [117]. Okereke et al. found BZ-3 in liver, spleen, 
heart and testes in rats after oral administration of BZ-3 [115]. There were large 
individual differences in excretion of BZ-3 among the volunteers, and this may be due 
to differences in enzyme activity. There is also enzyme activity in the skin, and both 
esterases and conjugation enzymes are present in the skin [118].  
 
During the time of the second study we encountered many technical obstacles when 
we were analyzing BZ-3. Several studies describe methods about HPLC and BZ-3 
but none of them fitted our purposes exactly. Sometimes the method did not work as 
described in the articles, or the method was not described in enough detail to enable 
us to reproduce it; for these reasons we developed our own method (Paper III). Many 
of the previously described studies are developed for product evaluation and not for 
in-vivo analysis. In some methods the biological samples were spiked with BZ-3; 
hence no biological influence such as metabolism etc. needed to be taken into 
consideration [111]. 
Our study had detection limits of 0.01 μmol/l and 0.16 μmol/l for BZ-3 and DHB 
respectively. These are at the same (or lower) levels as in other methods (Table 6), 
and the detection limits were sufficient to analyze the samples on day 10. We have 
described the method in detail to facilitate its reproduction by other researchers. The 
method was applied to measure BZ-3 and DHB and to study the excretion pattern. 
DHB was also extensively conjugated and excreted in the urine. 
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BZ-3 and DHB were always excreted in a similar pattern but the excretion pattern 
differed among the individuals. This may be due to different enzyme activity.  
 
There are few studies about metabolism of BZ-3 in humans. Hopefully, our work has 
made a small contribution to the research field. In rat, BZ-3 is metabolized to DHB, 
DHMB and THB. Urine seems to be the major metabolic pathway and DHB and THB 
the major metabolites in urine. DHMB was found solely in trace amounts. Only a 
smaller part of BZ-3 was excreted in faeces, and in faeces DHMB was the major 
metabolite [115, 119]. Okereke et al. also found differences between rat and mouse 
after oral administration of BZ-3. Tissue studies showed the highest amount of BZ-3 
in the liver for both rat and mouse, but in mice the elimination was split between urine 
and faeces with THB as the major metabolite. This may be due to enzyme 
differences between the species [116]. 
Toxicity studies have not shown any mutagenicity in Salmonella typhimurium strains 
for BZ-3 or DHB [120]. LD50 for rat was 7,400 mg/kg after oral administration of BZ-3 
[45]. For THB and DHMB no records of toxicity were available at the HSDB 
Hazardous Substances Data Bank [121].  
 
Shall we forbid products with BZ-3? I do not think so; after all, sunscreens are 
supposed to be used as a complement to other forms of sun protection, such as 
clothes and shade. BZ-3 is a relatively photostable compound and it gives good 
protection in the UVA region, so it has its place in the sunscreen market. Hayden et 
al. showed no keratinocyte toxicity after incubation of human keratinocytes and BZ-3 
in a normal dose [122]. However, it is prudent not to use it for children under the age 
of 24 months, for the reasons mentioned earlier. 
 
Photostability has been an issue for sunscreens for many years. It is well-known that 
some photoactive compounds and combinations of photoactive compounds are 
photounstable. There are mainly four reactions that can occur: 
photoaddition/substitution, cycloaddition, isomerization and photofragmentation. After 
the excited molecule has absorbed the UV, it can return to its ground state or 
produce isomers or new photoproducts. Evidently the former is preferred [123]. 
Schwack and Rudolph showed in 1995 that BMDBM is photounstable and about a 
dozen photoproducts were identified [124]. Bonda et al. showed 1999 that the 
combination of EHMC and BMDBM is photounstable, which other studies also show 
[125, 126]. 
 
BMDBM is a very popular compound since it is a UVA absorber. It was included in 
six of our seven investigated sunscreens (Table 8, p.25). A previous study has 
shown that photoactive ingredients in petrolatum are photounstable [127]. In 
commercially available products stabilizing agents may be added to the vehicle, and 
some combinations of photoactive compounds may be more stable than others.  
In our study (Paper IV) we could clearly see that this was not always the case. The 
combination of EHMC and BMDBM was used in three products. FDA does not 
recommend this combination [128] and it has been known for several years that this 
combination is photounstable, regardless of which other photoactive compounds are 
included in addition. Irradiation of EHMC and BMDBM leads to photocycloaddition 
creating cinnamate dimers and cyclobutylketone photoadducts which fragmented into 
new compounds [129].
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Green et al. showed that regular use of a sunscreen, containing EHMC and BMDBM, 
gave protection against AK and SCC, but they did not find any protective effect on  
BCC or CMM. This may be due to the fact that the combination is photounstable and 
if the study had been done with a photostable product, the result might have differed 
[51]. 
 
There is no standard method to measure photostability, and several methods are 
currently in use, both in-vivo and in-vitro methods [130-133]. Most of them use a 
spectrophotometer, but there are also studies with HPLC [134] or combinations with 
HPLC and spectrophotometry [135]. Few studies have been done using natural 
sunlight [133]. The photostability of a sunscreen is rarely presented on the final 
product.  
 
Our proposed method, the AUCI, can be a helpful tool in measuring the 
photostability. We chose to set the limit for photostability at AUCI >0.80 but this can 
of course be modified depending on the set-up. 
 
There are already many excellent commercially available sunscreens, and much 
research is being done to enhance photostability [136-139]. Many patent applications 
about enhancement of photostability have been published. TiO2 may also work as a 
stabilizer for photounstable drugs such as ketoprofen [140].  
 
In the future I hope it will be easier for the consumer to choose a sunscreen by also 
adding photostability testing on the final product. As mentioned before, sunscreens 
are a complement to clothes and shade in order to decrease our exposure to UVR. 
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CONCLUSIONS 
BZ-3 is absorbed by the skin and excreted in the urine after one topical application of 
a sunscreen. There are individual differences in the amount excreted and in the 
excretion pattern. (Paper I) 
 
Repeated topical applications of a sunscreen containing BZ-3 lead to a higher 
excretion of BZ-3. There was no statistical difference after exposure to UVR  
As in Paper I there are large individual differences. (Paper II) 
 
The developed HPLC method was reliable and suitable for handling a large number 
of samples. Three different excretion patterns were discerned among the volunteers. 
BZ-3 and DHB were excreted in a similar pattern in each volunteer. (Paper III) 
 
Three of the seven investigated sunscreens were photounstable in the UVA region. 
The combination of EHMC and BMDBM was unstable regardless of which other 
photoactive compounds were included. Our proposed method, the AUCI, can be a 
helpful tool in measuring the photostability. (Paper IV)  
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FUTURE PROSPECTS 
Few studies have been done about the metabolism of BZ-3 in humans. Both skin 
metabolism and genotyping would be interesting fields to further investigate. 
 
Several non-invasive methods e.g. multi photon microscopy, exist to study the skin 
structure, and some of these methods can also be used to investigate different 
compounds through the skin. 
 
Some photoactive compounds, e.g. BMDBM form photoproducts after irradiation. 
There are few studies about the impact of these products on humans. Many 
interesting studies are waiting to be done in this area. Can the photoproducts cause 
photoallergic reactions or even be able to damage the DNA?  
 
What will be the new generation of sunscreens? Cyanobacteria might help us to 
invent new products. 
 
Organ transplant recipients are a group especially vulnerable to skin cancer, because 
of their immunosuppressive therapy. In the future I hope we will develop programmes 
to protect them better, and effective sunscreens may be a part of such a programme. 
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